67-92-5
中文名稱
鹽酸雙環(huán)維林
英文名稱
DICYCLOMINE HYDROCHLORIDE
CAS
67-92-5
分子式
C19H36ClNO2
分子量
345.95
MOL 文件
67-92-5.mol
更新日期
2024/03/22 17:31:02
67-92-5 結(jié)構(gòu)式
基本信息
中文別名
鹽酸雙環(huán)胺鹽酸雙環(huán)維林
英文別名
atumindyspas
Bentyl)
mamiesan
oxityl-p
bentomine
merbentyl
Magesan P
procyclomin
di-syntramine
所屬類別
分析化學(xué)：藥典標(biāo)準(zhǔn)品和雜質(zhì)標(biāo)準(zhǔn)品物理化學(xué)性質(zhì)
熔點(diǎn)164-166°C
儲存條件-20°C冷凍
溶解度H2O: 50 mg/mL
形態(tài)powder
顏色off-white
BCS Class2/4
EPA化學(xué)物質(zhì)信息2-Diethylaminoethyl bicyclohexyl-1-carboxylate hydrochloride (67-92-5)
安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H302-H315-H319-H335
危險(xiǎn)品標(biāo)志Xn
危險(xiǎn)類別碼22-36/37/38
安全說明26-36
WGK Germany3
RTECS號DT7350000
海關(guān)編碼2922199695
毒性LD50 orl-rat: 1290 mg/kg DRUGAY 6,317,82
鹽酸雙環(huán)維林價(jià)格(試劑級)
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-B1339 | 鹽酸雙環(huán)維林 Dicyclomine hydrochloride | 67-92-5 | 100mg | 242元 |
| 2024/11/08 | HY-B1339 | 鹽酸雙環(huán)維林 Dicyclomine hydrochloride | 67-92-5 | 10mM * 1mLin DMSO | 266元 |
| 2024/11/08 | HY-B1339 | 鹽酸雙環(huán)維林 Dicyclomine hydrochloride | 67-92-5 | 500mg | 350元 |
常見問題列表
生物活性
Dicyclomine hydrochloride 是一種有效的口服活性毒蕈堿膽堿能受體 (muscarinic cholinergic receptors) 拮抗劑。Dicyclomine hydrochloride 對 M1 受體亞型 (Ki=5.1 nM) 和 M2 受體亞型 (Ki=54.6 nM) 在刷緣膜和基底質(zhì)膜中均表現(xiàn)出較高的親和力。Dicyclomine hydrochloride是一種抗痙攣試劑，在體內(nèi)可緩解胃腸道平滑肌痙攣。靶點(diǎn)
Ki: 5.1 nM (muscarinic M1 receptor subtype in brush-border membrane)Ki: 54.6 nM (muscarinic M2 receptor subtype in basal plasma membrane
體內(nèi)研究
Dicyclomine hydrochloride (intraperitoneal?injection; 8 mg/kg; daily) exacerbates the cognitive impairments in all the measurements. In addition, the memory impairments are worse in dicyclomine-treated 3xTg-AD mice compared to dicyclomine-treated NonTg mice.Dicyclomine hydrochloride (intraperitoneal injection; 2.0, 4.0, and 8.0 mg/kg; 7 days) produces a highly significant effect on performance in the paired-associates learning (PAL) task in mice.And systemic treatment at lower doses show behavioral impairments in mice in spatial tasks.
| Animal Model: | C57Bl/6 mice |
| Dosage: | 2.0, 4.0, and 8.0 mg/kg |
| Administration: | Intraperitoneal injection; daily; 7 days |
| Result: | Produced impairments due to actions of the agent outside of the hippocampus. |